Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes
A Meta-Analysis of Randomized Clinical Trials
Hussam Abuissa, MD*,
Philip G. Jones, MS,
Steven P. Marso, MD and
James H. O'Keefe, Jr, MD
Mid America Heart Institute, Cardiovascular Consultants, Kansas City, Missouri
View larger version (25K):
[in a new window]
|
Figure 1 Pooled risk estimates of the different angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) trials shown in Table 1. DM = diabetes mellitus; other abbreviations as in Table 1.
|
|
|
